Oral combination of netupitant and palonosetron for the of nausea and vomiting induced by chemotherapy

Nausea and vomiting are the most frequent painful adverse event of chemotherapy. Uncontrolled nausea lead to a significant decrease in quality life patients, nutritional insufficiency, breaking chemotherapy therapy regimen. worsen result prognosis disease. In clinical studies antiemetic drugs “complete response” is used as primary endpoint. The complete redponse absence need for additional drugs. oral combination netupitant palonosetron modern drug prevention induced by This includes highly selective anatagonist NK1-receptors at dose 300 mg an antagonist 5-HT3 receptors 0.5 mg. net-upitant has high compliance, it prescribed once before makes possible achieve control acute (0-24 hours) delayed (24-120 with emetogenic randomized trial (n = 1455) AC (doxorubicin + cyclophosphamide), resulted response during general phase (0-120 73.3% patients. 78.4% patients palonosteron experienced “no effect on daily life” due vomiting. observational study real practice 1197), regimen cyclophosphamide) had 81% Adverse events when using minimal, constipation was noted 1-8% cases, headache 1.4-3.6% cases.